PEG minocycline-liposomes ameliorate CNS autoimmune disease.

PEG minocycline-liposomes ameliorate CNS autoimmune disease.

Blog Article

Minocycline is an oral tetracycline derivative with good bioavailability in the central nervous system (CNS).Minocycline, a potent inhibitor of matrix metalloproteinase (MMP)-9, attenuates disease activity in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).Potential adverse effects associated with long-term daily minocycline therapy in human patients are concerning.Here, we investigated whether less frequent treatment with long-circulating polyethylene glycol (PEG) minocycline Interval Multi-Objective Optimal Scheduling for Redundant Residential Microgrid With VESS liposomes are effective in treating EAE.Performing in vitro time kinetic studies of PEG minocycline-liposomes in human peripheral blood mononuclear cells (PBMCs), we determined that PEG minocycline-liposome preparations stabilized with CaCl(2) are effective in diminishing MMP-9 activity.

Intravenous injections of PEG minocycline-liposomes every five days were as effective in ameliorating clinical EAE as daily intraperitoneal injections of minocycline.Treatment of animals with PEG minocycline-liposomes significantly reduced the number of CNS-infiltrating leukocytes, and the overall expression of MMP-9 in the CNS.There was also a significant suppression of MMP-9 expression and proteolytic activity in splenocytes of treated animals, but not in CNS-infiltrating leukocytes.Thus, leukocytes gaining access to the brain and spinal cord require the same absolute amount of MMP-9 in all treatment groups, but minocycline decreases the absolute cell number.Our data indicate that Apprendere al museo la musica come storia: didattica museale e costruzione delle conoscenze storico-musicali less frequent injections of PEG minocycline-liposomes are an effective alternative pharmacotherapy to daily minocycline injections for the treatment of CNS autoimmune diseases.

Also, inhibition of MMP-9 remains a promising treatment target in EAE and patients with MS.